1. Home
  2. ANAB vs CYD Comparison

ANAB vs CYD Comparison

Compare ANAB & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

N/A

Current Price

$48.43

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

N/A

Current Price

$32.15

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ANAB
CYD
Founded
2005
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2015
1998

Fundamental Metrics

Financial Performance
Metric
ANAB
CYD
Price
$48.43
$32.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
★ $88.50
$59.03
AVG Volume (30 Days)
★ 441.4K
103.5K
Earning Date
09-21-2026
08-07-2026
Dividend Yield
N/A
★ 2.80%
EPS Growth
★ 91.02
N/A
EPS
N/A
★ N/A
Revenue
★ $234,603,000.00
N/A
Revenue This Year
$17.97
$13.33
Revenue Next Year
$36.88
$9.34
P/E Ratio
★ N/A
$32.71
Revenue Growth
★ 157.01
N/A
52 Week Low
$29.49
$28.65
52 Week High
$73.30
$61.48

Technical Indicators

Market Signals
Indicator
ANAB
CYD
Relative Strength Index (RSI) 33.62 32.30
Support Level $49.93 N/A
Resistance Level $51.67 $35.66
Average True Range (ATR) 2.07 1.55
MACD -0.37 -0.02
Stochastic Oscillator 13.66 23.70

Price Performance

Historical Comparison
ANAB
CYD

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: